Which hedge funds own RPRX? ROYALTY PHARMA PLC, Q2 2026 13F holders
Healthcare · Open on the interactive board
13 of the hedge funds tracked by WhaleCreep disclosed a position in RPRX (ROYALTY PHARMA PLC) in their Q2 2026 13F filings, worth $1.2bn in total. The largest holder by portfolio weight is Baillie Gifford at 0.9% of its book. 2 managers opened a new position this quarter: Bridgewater Associates, Millennium Management. 1 exited: Farallon Capital Management.
13tracked managers holding
2opened this quarter
1exited this quarter
Which hedge funds hold RPRX? Current holders by portfolio weight
| Manager | As of | Weight of book | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|
| Baillie Gifford | Q2 2026 | 0.9% | $800.6m | 10,015,578 | -38% | reduced |
| Horizon Kinetics | Q2 2026 | 0.2% | $19.3m | 344,861 | 1% | added |
| Renaissance Technologies LLC | Q2 2026 | 0.1% | $108.5m | 1,935,800 | 145% | added |
| Tudor Investment | Q2 2026 | 0.1% | $34.2m | 610,736 | -9% | reduced |
| Marshall Wace | Q2 2026 | 0.1% | $137.4m | 2,450,669 | 16% | added |
| Brevan Howard Capital Management | Q2 2026 | 0.1% | $4.6m | 82,435 | 4% | added |
| Bridgewater Associates | Q2 2026 | 0.1% | $12.3m | 219,687 | – | new |
| Citadel Advisors | Q2 2026 | 0.0% | $76.0m | 1,354,640 | -49% | reduced |
| D. E. Shaw & Co | Q2 2026 | 0.0% | $29.4m | 525,114 | -53% | reduced |
| Point72 Asset Management LP | Q2 2026 | 0.0% | $6.0m | 106,549 | -78% | reduced |
| Woodline Partners | Q2 2026 | 0.0% | $1.3m | 23,330 | 48% | added |
| Holocene Advisors | Q2 2026 | 0.0% | $265.1k | 4,728 | -47% | reduced |
| Millennium Management | Q2 2026 | 0.0% | $675.3k | 12,043 | – | new |
Exited since the previous quarter
| Manager | Prior weight | Prior value |
|---|---|---|
| Farallon Capital Management | 1.0% | $23.6m |
How has hedge fund ownership of RPRX changed?
| Quarter | Managers holding | Combined value |
|---|---|---|
| Q2 2026 | 13 | $1.2bn |
| Q1 2026 | 12 | $2.0bn |
| Q4 2025 | 6 | $1.4bn |
| Q3 2025 | 4 | $331.7m |
| Q2 2025 | 5 | $1.4bn |
| Q1 2025 | 6 | $906.5m |
| Q4 2024 | 6 | $596.6m |
| Q3 2024 | 6 | $613.4m |
| Q2 2024 | 7 | $747.6m |
| Q1 2024 | 9 | $618.2m |
| Q4 2023 | 8 | $675.8m |
| Q3 2023 | 9 | $1.1bn |
| Q2 2023 | 9 | $1.3bn |
| Q1 2023 | 8 | $853.4m |
| Q4 2022 | 8 | $1.6bn |
| Q3 2022 | 6 | $882.5m |
Counts every tracked manager that disclosed RPRX in that quarter's filing, including managers that have since stopped filing.